

**Remarks**

***Status of the Claims and Support for the Amendment***

Claim 1 has been amended to recite the limitation of previously pending claim 10. Claims 13 and 14 have been amended to depend from claim 1. These amendments do not add any new matter.

Claim 10 has been canceled.

Claims 1 and 11-14 are pending in this application.

***Rejection Under 35 U.S.C. § 112, first paragraph***

Claims 1, 11 and 12 were rejected under 35 U.S.C. § 112, first paragraph as allegedly failing to comply with the written description requirement. According to the Examiner, one of skill in the art would not reasonably conclude that the Applicants were in possession of the genus of secondary plasmacytoid dendritic cell markers. Although Applicants disagree with the Examiner's rejection, the claims have been amended to recite two secondary plasmacytoid dendritic cell markers - - type 1 IFN and MXA. Applicants respectfully submit that this amendment obviates the rejection.

***Conclusion***

It is believed that this application is now in condition for allowance. If any issues remain after entry of this Amendment, Applicants invite the Examiner to contact the undersigned attorney by telephone.

Respectfully submitted,



**Gloria M. Fuentes**

Attorney for Applicants

Registration No. 47,580

Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1, 1990  
Kenilworth, NJ 07033  
Tel: (908) 298-2266  
Fax: (908) 298-5388